HLS THERAPEUTICS INC (HLS.CA) Forecast, Price Target & Analyst Ratings

Name: HLS THERAPEUTICS INC (HLS.CA) Analyst Consensus Rating
Brand: HLS THERAPEUTICS INC
Rating: 8 (8 reviews)

TSX:HLS • CA40390B1094

4.38 CAD

-0.01 (-0.23%)

Last: Mar 26, 2026, 07:00 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HLS THERAPEUTICS INC (HLS.CA).

Consensus Price Target

Price Target

CA$8.35

+ 90.67% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 6, 2026
Period: Q1 / 2026
EPS Estimate: -$0.12
Revenue Estimate: 13.332M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

80.00%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

CA$8.35

Upside

+ 90.67%

From current price of CA$4.38 to mean target of CA$8.35, Based on 8 analyst forecasts

Low

CA$4.80

Median

CA$8.16

High

CA$12.60

Price Target Revisions

1 Month

0.00%

3 Months

9.90%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for HLS.CA. The average price target is 8.35 CAD. This implies a price increase of 90.67% is expected in the next year compared to the current price of 4.38.

The average price target has been revised upward by 9.9% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

80.00%

HLS.CA was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about HLS.CA.

In the previous month the buy percentage consensus was at a similar level.

HLS.CA was analyzed by 8 analysts. More opinions would make the average more meaningful.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2022-11-11	Stifel Nicolaus Research	Downgrade
2022-10-26	Stifel Nicolaus Research	Maintains	Buy
2022-08-25	Raymond James Capital	Downgrade	Outperform
2022-08-12	Stifel Nicolaus Research	Downgrade
2022-05-06	Raymond James Capital	Initiate	Outperform
2022-04-27	Clarus Securities	Reiterate	Buy
2022-04-27	Raymond James Capital	Upgrade	Outperform
2022-03-21	Clarus	Initiate	Buy
2022-03-20	Raymond James Capital	Initiate	Outperform
2022-03-20	Canaccord Capital	Downgrade	Buy
2022-03-15	Raymond James Capital	Initiate	Outperform
2022-03-10	Stifel Nicolaus Research	Initiate	Buy
2021-12-16	Raymond James Financial	Initiate	Outperform
2021-11-05	RJ Financial	Initiate	Outperform
2021-10-28	Raymond James Financial	Initiate	Outperform
2021-08-17	Raymond James Financial	Upgrade	Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 6, 2026
Period: Q1 / 2026
EPS Estimate: -$0.12
Revenue Estimate: 13.332M
Revenue Q2Q: 5.62%
EPS Q2Q: 13.43%
Number of Analysts: 3

Next Earnings Revisions

Revenue (1 Month)

1.54%

Revenue (3 Months)

-2.59%

EPS (1 Month)

-50.00%

EPS (3 Months)

-50.00%

Next Earnings Summary

HLS.CA is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.12 CAD and the consensus revenue estimate is 13.33M CAD.

The next earnings revenue estimate has been revised downward by 2.59% in the past 3 months.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028	2029	2030
Revenue YoY % growth	63.074M 2.56%	56.619M -10.23%	55.5M -1.98%	61.307M 10.46%	69.337M 13.10%	66.913M -3.50%	71.649M 7.08%	75.346M 5.16%
EBITDA YoY % growth	20.129M -3.69%	13.523M -32.82%	16.333M 20.78%	22.153M 35.63%	25.705M 16.03%	34.542M 34.38%	40.4M 16.96%	45.955M 13.75%
EBIT YoY % growth	-11.81M 12.52%	-9.194M 22.15%	-5.484M 40.35%	-4.646M 15.28%	1.212M 126.09%	6.06M 400.00%	16.16M 166.67%	21.715M 34.38%
Operating Margin	-18.72%	-16.24%	-9.88%	-7.58%	1.75%	9.06%	22.55%	28.82%
EPS YoY % growth	-0.85 -44.07%	-0.62 27.06%	-0.39 37.10%	-0.25 36.55%	-0.05 79.59%	0.14 380.00%	0.32 128.57%	0.51 56.25%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26
EPS Q2Q % growth	-0.12 13.43%	-0.05 43.89%	-0.05 57.92%	-0.04 -1.00%
Revenue Q2Q % growth	13.332M 5.62%	16.16M 14.04%	16.16M 19.61%	17.17M 13.00%
EBITDA Q2Q % growth	4.04M 40.62%	5.858M -41.62%	6.06M -58.05%	6.363M -70.46%
EBIT Q2Q % growth	-2.525M -1.53%	-202K 75.03%	100.00%	303K 208.21%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

33.19%

EPS Next 5 Year

26.93%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

6.42%

Revenue Next 5 Year

6.30%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

107.85%

EBIT Next 5 Year

62.37%

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

HLS THERAPEUTICS INC / HLS.CA Forecast FAQ

What do analysts expect the price target to be for HLS THERAPEUTICS INC (HLS.CA)?

8 analysts have analysed HLS.CA and the average price target is 8.35 CAD. This implies a price increase of 90.67% is expected in the next year compared to the current price of 4.38.

What is the next earnings date for HLS stock?

HLS THERAPEUTICS INC (HLS.CA) will report earnings on 2026-05-06.

What are the consensus estimates for HLS stock next earnings?

The consensus EPS estimate for the next earnings of HLS THERAPEUTICS INC (HLS.CA) is -0.12 CAD and the consensus revenue estimate is 13.33M CAD.

How many analysts have analysed HLS THERAPEUTICS INC (HLS.CA)?

The number of analysts covering HLS THERAPEUTICS INC (HLS.CA) is 8.

Analyst forecast overview

Forecast Snapshot